Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad

Immunologic Research

Volumn 65, Issue 1, 2017, Pages 262-275

  Lazzerini, Pietro Enea ^a   Capecchi, Pier Leopoldo ^a   Galeazzi, Mauro ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Arrhythmic risk; Atrial fibrillation; Biologic drugs; Rituximab; Sudden cardiac death; Systemic inflammation; TNF inhibitors

Indexed keywords

ADALIMUMAB; ANAKINRA; ANTIARRHYTHMIC AGENT; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANGIOCARDIOGRAPHY; ARTICLE; ATRIAL FIBRILLATION; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MORBIDITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SUDDEN CARDIAC DEATH; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; ARTHRITIS; CHEMICALLY INDUCED; CHRONIC DISEASE; PATHOPHYSIOLOGY; RISK;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ARTHRITIS; BIOLOGICAL PRODUCTS; CHRONIC DISEASE; HUMANS; RISK;

EID: 84978904257     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-016-8833-7     Document Type: Article

References (120)

1. Hadam J, Aoun E, Clarke K, Wasko MC. Managing risks of TNF inhibitors: an update for the internist. Cleve Clin J Med. 2014;81:115–27.
2. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:639–52.
3. Johnsson HJ, McInnes IB. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S115–8.
4. Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31.
5. John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med. 2012;23:575–9.
6. Mantel Ä, Holmqvist M, Jernberg T, Wållberg-Jonsson S, Askling J. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J. 2015;36:3413–22.
7. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402–11.
8. Ungprasert P, Srivali N, Kittanamongkolchai W. Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2015. doi:10.1111/1756-185X.12820.
9. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2016. doi:10.1093/eurheartj/ehw208.
10. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–82.
11. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014;13:936–44.
12. Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology. 2014;53:131–7.
13. Chauhan K, Ackerman M, Crowson CS, Matteson EL, Gabriel SE. Population-based study of QT interval prolongation in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:84–9.
14. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34(585–5):92.
15. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72:211–6.
16. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, Maksymowych WP. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294–304.
17. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res. 2011;63:557–63.
18. Chiu HY, Chang WL, Huang WF, Wen YW, Tsai YW, Tsai TF. Increased risk of arrhythmia in patients with psoriatic disease: a nationwide population-based matched cohort study. J Am Acad Dermatol. 2015;73:429–38.
19. Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide cohort study. Eur Heart J. 2012;33:2054–64.
20. Keller JJ, Hsu JL, Lin SM, Chou CC, Wang LH, Wang J, Bai CH, Chiou HY. Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. Rheumatol Int. 2014;34:255–63.
21. Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S, Bisogno S, Barreca C, Galeazzi M, Laghi-Pasini F. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med. 2013;24:368–74.
22. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med. 2015;2:26.
23. Simsek H, Sahin M, Akyol A, Akdag S, Ozkol HU, Gumrukcuoglu HA, Gunes Y. Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. Sci World J. 2013;2013:901215.
24. Bacaksiz A, Erdogan E, Tasal A, Vatankulu MA, Kul S, Sevgili E, Ertas G, Dizman D, Onsun N, Uysal O. Electrocardiographic P-wave characteristics in patients with psoriasis vulgaris. Ups J Med Sci. 2013;118:35–41.
25. Borman P, Gokoglu F, Kocaoglu S, Yorgancioglu ZR. The autonomic dysfunction in patients with ankylosing spondylitis: a clinical and electrophysiological study. Clin Rheumatol. 2008;27:1267–73.
26. Acar G, Yorgun H, Inci MF, Akkoyun M, Bakan B, Nacar AB, Dirnak I, Cetin GY, Bozoglan O. Evaluation of Tp-e interval and Tp-e/QT ratio in patients with ankylosing spondylitis. Mod Rheumatol. 2014;24:327–30.
27. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121:S21–31.
28. Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, Crow MK, Sammaritano L, Levine DM, Salmon JE. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum. 2009;60:22–9.
29. Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, Borgeson DD, Therneau TM, Rodeheffer RJ, Gabriel SE. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis. 2010;69:1665–70.
30. Kobayashi Y, Giles JT, Hirano M, Yokoe I, Nakajima Y, Bathon JM, Lima JA, Kobayashi H. Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Res Ther. 2010;12:R171.
31. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9–14.
32. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167–72.
33. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–7.
34. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006;54:60–7.
35. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754–63.
36. Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Heart Rhythm. 2011;8:1963–8.
37. Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin. 2010;6:187–200.
38. Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007;87:425–56.
39. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62–73.
40. Elenkov IJ, Wilder RL, Chrousos GP, Vizi S. The sympathetic nerve: an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638.
41. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853–9.
42. Martelli D, Yao ST, McKinley MJ, McAllen RM. Reflex control of inflammation by sympathetic nerves, not the vagus. J Physiol. 2014;592:1677–86.
43. Anderson KP. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann Noninvasive Electrocardiol. 2003;8:75–89.
44. Wu CT, Nattel S. Triggering of cardiac arrhythmic events in long QT syndrome: lessons from funny bunnies. J Physiol. 2012;590:1311–2.
45. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480–9.
46. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905–12.
47. Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, Pavlidis G, Parissis J, Kremastinos D, Anastasiou-Nana M, Lekakis J. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7:619–28.
48. Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG. The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, Abatacept and tociliziumab. PLoS One. 2015;10:e0130709.
49. Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67:372–80.
50. Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F. Antiarrhythmic potential of anti-cytokine therapy in rheumatoid arthritis: tocilizumab reduces QTc interval by controlling systemic inflammation. Arthritis Care Res. 2015;67:332–9.
51. Senel S, Cobankara V, Taskoylu O, Guclu A, Evrengul H, Kaya MG. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis. J Investig Med. 2011;59:1273–5.
52. Di Franco M, Paradiso M, Ceccarelli F, Scrivo R, Spinelli FR, Iannuccelli C, Valesini G. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion. J Rheumatol. 2012;39:41–5.
53. Lazzerini PE, Acampa M, Hammoud M, Maffei S, Capecchi PL, Selvi E, Bisogno S, Guideri F, Galeazzi M, Pasini FL. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol. 2008;35:1958–65.
54. Syngle A, Verma I, Krishan P, Garg N, Syngle V. Disease-modifying anti-rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study. Clin Rheumatol. 2015;34:1233–41.
55. Syngle A, Verma I, Krishan P. Interleukin-6 blockade improves autonomic dysfunction in rheumatoid arthritis. Acta Reumatol Port. 2015;40:85–8.
56. Meek IL, Vonkeman HE, van de Laar MA. Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature. BMC Musculoskelet Disord. 2014;15:142.
57. Remicade: Infliximab. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
58. Enbrel: Etanercept. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
59. Humira: Adalimumab. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
60. Cimzia: Certolizumab pegol. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
61. Simponi: Golimumab. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
62. MabThera: Rituximab. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
63. RoActemra: Tocilizumab. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
64. Kineret: Anakinra. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
65. Stelara: Ustekinumab. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
66. Orencia: Abatacept. Product information: summary of product characteristics. European Medicine Agency (EMA). http://www.ema.europa.eu.
67. Clari F, Salani I, Safwan E, Giannacco A. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-α have protective effects on failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation. 2002;105:E183.
68. Boyer JF, Jamard B, El Mahou S, Laroche M, Mazieres B, Cantagrel A, Constantin A. New-onset acute heart failure and ventricular tachycardia after therapy with a tumor necrosis factor antagonist. Clin Exp Rheumatol. 2005;23:274–5.
69. Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Stawczyk-Eder K, Linke K. Ventricular tachyarrhythmia after adalimumab therapy in a patient with Crohn’s disease. Acta Gastroenterol Belg. 2013;76:74–5.
70. Ozcan OU, Ozcan DS, Polat CS, Ozyuncu N, Erol C. Ventricular arrhythmia with cessation of infliximab in a patient with ankylosing spondylitis. J Ankara Univ Fac Med. 2015;68:77–9.
71. Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000;72:517–9.
72. Choi JW, Tae HJ, Oh IH, Lee MK, Shin JH, Kim TH, Jun JB, Uhm WS. A case of atrial fibrillation induced by infliximab in a patient with rheumatoid arthritis. J Rheum Dis. 2011;18:302–5.
73. Singh M, Diwan MM, Patel KC. A rare case of supraventricular tachycardia induced by infliximab: a case report. Cases J. 2009;2:147.
74. Sood A, Midha V. Symptomatic sinus bradycardia with infliximab. Indian J Gastroenterol. 2004;23:118–9.
75. Sofos S, Savoye G, Ramirez S, Bauer F, Lerebours E. Transient type III atrioventricular block after infliximab infusion in a fistulizing perianal Crohn’s disease patient. Am J Gastroenterol. 2007;102:217–9.
76. Sote Y, Green S, Maddison P. Complete heart block after infliximab therapy. Rheumatology. 2008;47:227–8.
77. Anand CP, Al-Juburi A, Bhargava S. Heart block occurring during infliximab infusion: a report of two cases. Am J Gastroenterol. 2003;98:S144.
78. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012;18:1543–55.
79. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317–24.
80. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
81. Moreno M, Sancho JM, Gardella S, Coll R, García O, Gallardo D, Ribera JM. Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin’s lymphoma: study of 26 patients. Med Clin. 2010;30(134):72–5.
82. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R, GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transpl. 2007;40:273–7.
83. Tournamille JF, Rigal-Huguet F, Pathak A, Montastruc JL, Lapeyre-Mestre M. Cardiac effects of cytokines produced after rituximab infusion. Bull Cancer. 2005;92:769–71.
84. van Sijl AM, van der Weele W, Nurmohamed MT. Myocardial infarction after rituximab treatment for rheumatoid arthritis: is there a link? Curr Pharm Des. 2014;20(4):496–9.
85. Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J. 2010;37:218–20.
86. Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol. 2005;78:317–8.
87. Passalia C, Minetto P, Arboscello E, Balleari E, Bellodi A, Del Corso L, Molinari E, Ponassi I, Oneto C, Sicbaldi V, Ghio R. Cardiovascular adverse events complicating the administration of rituximab: report of two cases. Tumori. 2013;99:288e–92e.
88. Sheikh M, Moza A, Grubb BP. Rituximab induced left bundle branch block. Heart Views. 2015;16:21–2.
89. Cervera Grau JM, Esquerdo Galiana G, Belso Candela A, Llorca Ferrándiz C, Juárez Marroquí A, Maciá Escalante S. Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma. Clin Transl Oncol. 2008;10:298–9.
90. Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807–11.
91. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–4310.
92. Hofbauer KH, Schoof E, Kurtz A, Sandner P. Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathways. Hypertension. 2002;39:161–7.
93. Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis. 2004;177:113–8.
94. Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol Rev. 2006;14:50–2.
95. Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn’s disease. World J Gastroenterol. 2006;12:6235–8.
96. Kumar A, Ghose T, Mendiratta N, Prajapati PK, Abrol A. Acute coronary syndrome caused by infliximab in a patient with ankylosing spondylitis. Int J Rheum Dis. 2013;16:235–6.
97. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005;4:153–61.
98. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–57.
99. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–1316.
100. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol. 1999;14:206–10.
101. Rossi MA, Celes MR, Prado CM, Saggioro FP. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock. 2007;27:10–8.
102. Zhang XJ, Yue J, Zhao TB. Expression change of TNF-α in myocardium and hepatic tissue of rats with compound stress of hyperthermia and lipopolysaccharide. Asian Pac J Trop Med. 2013;6:300–4.
103. Bonnemeier H, Wiegand UKH, Brandes A, Kluge N, Katus HA, Richardt G, Potratz J. Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol. 2003;14:8791–9.
104. Tvede N, Nielsen LP, Andersen V. Bradycardia after high-dose intravenous methylprednisolone therapy. Scand J Rheumatol. 1986;15:302–4.
105. Pudil R, Hrncir Z. Severe bradycardia after a methylprednisolone “minipulse” treatment. Arch Intern Med. 2001;161:1778–9.
106. Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics. 2007;119:e778–82.
107. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–24.
108. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4:1357–60.
109. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transpl. 2006;6:859–66.
110. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183:949–58.
111. Hofmann U, Heuer S, Meder K, Boehler J, Lange V, Quaschning T, Ertl G, Bonz A. The proinflammatory cytokines TNF-alpha and IL-1 beta impair economy of contraction in human myocardium. Cytokine. 2007;39:157–62.
112. Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, Halvorsen B, Ueland T. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med. 2011;43:90–103.
113. Armitage JD, Montero C, Benner A, Armitage JO, Bociek G. Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma. 2008;8:253–5.
114. Roy A, Khanna N, Senguttuvan NB. Rituximab-vincristine chemotherapy-induced acute anterior wall myocardial infarction with cardiogenic shock. Tex Heart Inst J. 2014;41:80–2.
115. Gogia A, Khurana S, Paramanik R. Acute myocardial infarction after first dose of rituximab infusion. Turk J Haematol. 2014;31:95–6.
116. Arunprasath P, Gobu P, Dubashi B, Satheesh S, Balachander J. Rituximab induced myocardial infarction: a fatal drug reaction. J Cancer Res Ther. 2011;7:346–8.
117. Nikolaidis LA. When cancer and heart failure cross paths: a case report of severe cardiorenal compromise associated with the anti-CD20 monoclonal antibody rituximab in a patient with dilated cardiomyopathy. Congest Heart Fail. 2001;7:223–7.
118. Renard D, Cornillet L, Castelnovo G. Myocardial infarction after rituximab infusion. Neuromuscul Disord. 2013;23:599–601.
119. Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, Brecher ME. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005;45:1481–6.
120. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–66.